Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 108,100 shares, a decline of 47.7% from the October 15th total of 206,700 shares. Based on an average daily volume of 905,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 27.4% of the shares of the stock are short sold.

Avalon GloboCare Stock Performance

Avalon GloboCare stock opened at $3.02 on Friday. The business’s fifty day moving average is $3.34 and its two-hundred day moving average is $4.89. The firm has a market cap of $3.23 million, a P/E ratio of -0.15 and a beta of 0.31. Avalon GloboCare has a 52 week low of $2.11 and a 52 week high of $21.60.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Monday, August 19th. The company reported ($2.85) earnings per share (EPS) for the quarter. The company had revenue of $0.33 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.